BioXcel Therapeutics, Inc. Balance Sheet
BTAI|4 years of annual SEC 10-K data (FY2022-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
BioXcel Therapeutics, Inc. had $45M in total assets with negative shareholders' equity of $95M as of FY2025. Total debt was $110M against $28M in cash, resulting in $81M net debt.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash & Equivalents | $28.4M | $29.9M | $65.2M | $193.7M |
| Inventory | $722.0K | $679.0K | $2.0M | $2.0M |
| Current Assets | $44.7M | $37.4M | $72.1M | $202.9M |
| PP&E (Net) | $175.0K | $475.0K | $784.0K | $1.1M |
| Total Assets | $44.9M | $38.3M | $73.7M | $205.9M |
| Current Liabilities | $53.9M | $22.2M | $27.3M | $32.9M |
| Total Debt | $109.6M | $102.5M | $100.6M | $93.1M |
| Shareholders' Equity | -$95.5M | -$56.5M | $76.8M | $221.7M |